North Carolina is currently home to 2655 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
Recruiting
This is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatment of painful vertebral compression fragility fractures (VCFs). The objective of this study is to demonstrate non-inferiority of the AGN1 LOEP SV Kit for the treatment of VCFs to standard of care vertebroplasty treatment using bipedicular injection of PMMA bone cement.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/27/2025
Locations: Pinehurst Surgical Clinic, Pinehurst, North Carolina
Conditions: Vertebral Compression Fracture, Compression Fracture, Vertebral Compression
GSD VI and GSD IX Natural History
Recruiting
Collection and review of clinical information related to Glycogen Storage Disease Type VI (GSD VI) OR Glycogen Storage Disease Type IX (GSD IX) generated during clinic visits.
Gender:
ALL
Ages:
Between 0 years and 90 years
Trial Updated:
05/27/2025
Locations: Duke University, Durham, North Carolina
Conditions: Glycogen Storage Disease VI, GLYCOGEN STORAGE DISEASE IXa1, GLYCOGEN STORAGE DISEASE IXa2, Glycogen Storage Disease IXB, Glycogen Storage Disease IXC, GSD 9 (All Subtypes), GSD 6
Adolescents Living With HIV (ALWH): Social Networks, Adherence and Retention
Recruiting
human immunodeficiency virus / acquired immunodeficiency syndrome (HIV/AIDS) is the second leading cause of death in Africa. Adolescents living with HIV (ALWH) are at increased risk for HIV-related morbidity and mortality due to poor retention in HIV care and suboptimal antiretroviral therapy (ART) adherence. Despite having the world's largest population of Adolescents living with HIV (ALWH) (15-24 years, n=870,000), only 14% of South African ALWH are on ART, 12% are retained in HIV care 1-2 yea... Read More
Gender:
ALL
Ages:
Between 15 years and 21 years
Trial Updated:
05/27/2025
Locations: Wake Forest University School of Medicine, Winston-Salem, North Carolina
Conditions: HIV/AIDS
Prospective Measurement of Normal Venous Sinus Pressures
Recruiting
The purpose of this research is to document normal intracranial venous sinus pressures. Participants who need to have a cerebral angiogram to evaluate a medical problem not related to Idiopathic Intracranial Hypertension (IIH) will be invited to participate. Participation in this research will not require any extra visits. The intervention will take place in the interventional radiology suite when the subject has an angiogram. IIH is a condition that causes increased pressure in the brain in the... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/27/2025
Locations: Wake Forest Univesity Health Sciences, Winston-Salem, North Carolina
Conditions: Intracranial Venous Pressures
Ferritin and Iron Burden in SAH sIRB
Recruiting
Ruptured cerebral aneurysms lead to subarachnoid hemorrhage (SAH),that has a high morbidity and mortality rate, the severity of which is predicted by the "Hunt-Hess grade" (HHG). SAH leads to iron (Fe) and hemoglobin (Hb) accumulation in the brain, which is toxic for neurons. Ferritin (iron reported in the brian) and iron overload leads to brain atrophy, specifically in the mesial temporal lobe (hippocampus, impairing patients' cognition. It is estimated that 50% of survivors have cognitive def... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/27/2025
Locations: Duke University Health System, Durham, North Carolina
Conditions: SAH, Dementia
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
Recruiting
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Gender:
ALL
Ages:
Between 11 years and 75 years
Trial Updated:
05/27/2025
Locations: Wake Forest University, Winston-Salem, North Carolina
Conditions: Huntington's Disease
GBE Deficiency (GSD IV and APBD) Natural History Study
Recruiting
Collection and review of clinical information related to glycogen branching enzyme (GBE) deficiency, diagnosed as Glycogen Storage Disease Type IV (GSD IV) or Adult Polyglucosan Body Disease (APBD generated during clinic visits.
Gender:
ALL
Ages:
Between 0 years and 90 years
Trial Updated:
05/27/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Glycogen Storage Disease Type IV, Adult Polyglucosan Body Disease, GSD4, GSD IV, APBD
Muscle Fiber Fragment Treatment for Urinary Incontinence
Recruiting
This study is designed to evaluate the safety of autologous muscle fiber fragments for the treatment of urinary incontinence due to incompetent outlet (bladder neck/urethra).
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
05/27/2025
Locations: Wake Forest Urology Clinic, Winston-Salem, North Carolina
Conditions: Urinary Incontinence
Pharmacokinetics of Off Label Pediatric Medications
Recruiting
The purpose of this study is to measure the level of medicines found in body fluids such as blood, urine, spinal fluid of children.
Gender:
ALL
Ages:
Between 1 day and 8 years
Trial Updated:
05/27/2025
Locations: University of North Carolina NC Children's Hospital, Chapel Hill, North Carolina
Conditions: Off Label Use of Medications in Pediatric Patients
A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 6-week trial of a formulation of AMZ001 once daily versus placebo once daily.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
05/26/2025
Locations: West Clinical Research, Morehead City, North Carolina
Conditions: Osteoarthritis of Knee, Osteoarthritis, Knee
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Recruiting
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed. ABBV-291 is an investigational dr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: Carolina BioOncology Institute /ID# 265259, Huntersville, North Carolina
Conditions: Non-Hodgkin's Lymphoma
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Recruiting
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Multiple Myeloma